CSPC PHARMA 1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18
I'm LongbridgeAI, I can summarize articles.CSPC PHARMA reported a 139.2% YoY surge in H1 2026 net profit to RMB6.094 billion, driven by a 56.7% rise in finished drug revenue and a massive 448.5% jump in licensing fees. Gross margin expanded to 76.2%. The company declared an interim dividend of HKD0.18 per share, up 28.6% YoY. While bulk product and functional food revenues declined, overall financial performance showed strong growth.
CSPC PHARMA (01093.HK) +1.170 (+13.472%) Short selling $283.59M; Ratio 10.252% announced its interim results for the period ended June 2026. Revenue rose 40.1% YoY to RMB18.594 billion; net profit reached RMB6.094 billion, up 139.2% YoY; basic EPS was RMB0.5345. Under non-HKFRS, underlying profit amounted to RMB6.164 billion, up 165.8% YoY.
The board declared an interim dividend of HKD0.18 per share, representing an increase of 28.6% from HKD0.14 in the corresponding period last year.
Interim gross profit margin reached 76.2%, up 10.6 ppts from 65.6% in the corresponding period last year, mainly driven by a higher contribution from the finished drug business.
In 1H26, CSPC PHARMA's finished drug business revenue amounted to RMB16.061 billion, up 56.7% YoY. Among which, licensing fee income surged 448.5% to RMB5.895 billion; revenue from bulk product business fell 20% YoY to RMB1.66 billion; revenue from functional food and other businesses decreased 8.2% to RMB873 million.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-20 12:25.)
AASTOCKS Financial News